Table 3. Trial Implementation and Reporting.
| Variable | No. (%) |
|---|---|
| Screened patients included, median (IQR). % | 76.8 (45.1-95.2) |
| Patients lost to follow up, median (IQR) | 4.0 (0.0-17.0) |
| Sample size lost to follow up, median (IQR), % | 3.3 (0.0-10.7) |
| Fragility index, median (IQR) | 3.0 (1.0-6.0) |
| Fragility Index minus patients lost to follow up, median (IQR) | 0.0 (0.0-3.0) |
| Crossovers, median (IQR), No. | 1.0 (0.0-6.5) |
| Crossover, median (IQR), % | 0.5 (0.0-3.0) |
| Trials | |
| With a favorable outcome | 166 (42.7) |
| With a neutral outcome | 212 (54.6) |
| Multiplicity | 175 (45.1) |
| Multiple treatment groups | 13 (7.4) |
| Multiple outcomes | 66 (37.7) |
| Multiple analyses of the same outcome | 66 (37.7) |
| Multiple outcomes + multiple analyses of the same outcome | 23 (13.2) |
| Multiple treatment groups + multiple outcomes | 4 (2.3) |
| Multiple treatment groups + multiple analyses of the same outcome | 3 (1.7) |
| Adjusted for multiple comparisons | 35 (20.0) |
| Bonferroni correction | 25 (71.4) |
| Tukey test | 7 (20.0) |
| Dunn test | 1 (2.9) |
| Gatekeeping or hierarchical testing | 1 (2.9) |
| Modified α value | 1 (2.9) |
| Reporting bias present | 109/211 (51.7) |
| Extent of reporting bias | |
| None | 102 (48.3) |
| In 1 section other than conclusion | 11 (5.2) |
| In conclusion only | 34 (16.1) |
| In 2 sections | 33 (15.6) |
| In all sections | 31 (14.7) |
| Citations, median (IQR), No. | 36 (15-91) |
Abbreviation: IQR, interquartile range.